Results in 95 Hemorrhagic Stroke Patients Included in CLASS, a Controlled Trial of Clomethiazole Versus Placebo in Acute Stroke Patients | Zendy

Nils Wahlgren | Zendy; Exuperio Díez–Tejedor | Zendy; Jeanne Teitelbaum | Zendy; Adrià Arboix | Zendy; Didier Leys | Zendy; T. Ashwood | Zendy; Ehud Grossman | Zendy

Open Access

Results in 95 Hemorrhagic Stroke Patients Included in CLASS, a Controlled Trial of Clomethiazole Versus Placebo in Acute Stroke Patients

Author(s) -

Nils Wahlgren,

Exuperio Díez–Tejedor,

Jeanne Teitelbaum,

Adrià Arboix,

Didier Leys,

T. Ashwood,

Ehud Grossman

Publication year - 2000

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.31.1.82

Subject(s) - medicine , stroke (engine) , placebo , acute stroke , anesthesia , tissue plasminogen activator , alternative medicine , pathology , mechanical engineering , engineering

Clomethiazole is a neuroprotective drug that enhances gamma-aminobutyrate type A (GABA(A)) receptor activity. Its efficacy and safety were tested in the CLomethiazole Acute Stroke Study (CLASS). The protocol allowed a CT scan to be done after randomization but within 7 days of stroke onset to minimize delays before start of treatment. Ninety-five of the 1360 patients randomized were diagnosed as having intracranial hemorrhage rather than ischemic stroke. Safety results for clomethiazole compared with placebo in this group are reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research